Akums Drugs and Pharmaceuticals Limited Annual Report FY2026
Akums Drugs and Pharmaceuticals Limited Annual Report FY2026
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Akums Drugs and Pharmaceuticals is a dominant Contract Development and Manufacturing Organization (CDMO) in India, commanding a significant market share in the domestic pharmaceutical manufacturing landscape. The business has evolved from a private entity to a public one, significantly deleveraging its balance sheet following its IPO. While revenue has grown at a 10% CAGR over the last decade, profitability has been volatile, marked by a significant net loss in FY22 and a recovery thereafter. The business quality is characterized by high operational volume and a diverse SKU portfolio, yet…
Key Changes in FY2026
Akums has evolved from a pure-play CDMO established in 2004 into a comprehensive pharmaceutical solutions provider. The business has successfully expanded its dosage forms from simple tablets and capsules to complex injectables, blow-filled seals, and gummies. The recent acquisition of Oriflame's manufacturing unit marks an evolution into the wellness and personal care manufacturing segment. Geographic expansion and the pursuit of cumulative DCGI approvals demonstrate a transition from a local manufacturer to a research-led partner. The shift in the balance sheet, with fixed assets growing from ₹444 Cr in 2015 to ₹1,456 Cr in 2026, reflects a decade of aggressive capacity building. The business is clearly moving up the value chain by adding specialized manufacturing capabilities and…
Management Commentary
Management demonstrates deep industry domain expertise, having built the largest CDMO platform in India over two decades. The communication is characterized by a focus on SKU expansion, R&D investments, and deepening relationships with top-tier pharmaceutical clients. However, the FY22 financial dip suggests vulnerability to external shocks or misaligned cost structures during that period. Transparency has improved with the transition to a public company, evidenced by regular investor calls and detailed disclosures. The leadership is currently focused on premiumization and digital transformation to maintain its competitive edge in a crowded manufacturing market.
Financial Highlights
The financial profile reflects a business scaling significantly but struggling with margin consistency. Revenue grew from ₹1,464 Cr in FY15 to ₹4,359 Cr in FY26, representing a steady but non-explosive growth trajectory. Operating margins have fluctuated wildly between -2.4% and 12%, impacted by raw material pricing and operational overheads. The FY22 loss of ₹251 Cr stands as a significant historical outlier that necessitated capital restructuring. Recent years show a recovery in Profit Before Tax, reaching ₹382 Cr in FY26, though Return on Equity remains moderate at approximately 8.5%, indicating room for improvement in capital utilization.
Major Opportunities
- Significant debt reduction in FY25
- Strong FCF generation in FY26
- Leadership in Indian CDMO market
Major Risks
- Inconsistent bottom-line performance (Losses in 2022 and 2024)
- High regulatory risk inherent in pharma manufacturing
- Revenue growth (10% 5y CAGR) is moderate for the sector
About This Annual Report
The Akums Drugs and Pharmaceuticals Limited FY2026 Annual Report is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.
Why Use AI?
- Summarises hundreds of pages into a focused executive briefing
- Identifies year-on-year key changes automatically
- Extracts management commentary and tone
- Highlights top risks and opportunities
- Compares business evolution vs. earlier years
- Answers your questions in plain English via Ask AI
Frequently Asked Questions
Related Research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.